CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics
ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct lytic...
CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in...
New Combination of CFTR Mutations Found in Chinese Siblings With CF
A combination of two mutations, including one that had never been reported, were found in two Chinese siblings who developed a severe...
4DMT Receives Up to $14M from CFF for Development of Customized Gene Carrier
After being given more than $3 million from the Cystic Fibrosis Foundation (CFF) in 2017 to expand the development of viral vectors for...
Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows
Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to...
AzurRx BioPharma Will Conduct Phase 2b Trial of MS1819 at TDN Clinical Sites
AzurRx BioPharma has been authorized to conduct its Phase 2b OPTION 2 clinical trial evaluating MS1819, its investigative therapy for...